Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

UK MHRA approves Eli Lilly’s Inluriyo (imlunestrant tosylate) targeting estrogen receptor for locally advanced or metastatic breast cancer
Small molecule, cancer, selective estrogen receptor degrader, breast cancer, ESR1 mutation - Read more

Biocon receives FDA approval for gSaxenda (liraglutide) GLP-1 injection targeting chronic weight management
Protein therapy, metabolic, GLP-1 agonist, obesity, weight management, liraglutide - Read more

HekaBio and Alpha Tau Medical's Alpha DaRT wins Japan approval for head and neck cancer treatment
Radiation therapy, cancer, alpha particle therapy, head and neck cancer, solid tumors - Read more

Pfizer, Beam Therapeutics global license for liver-targeted gene editing candidate, $1.05B milestone potential
Licensing deal, gene editing, liver disease, milestone payments - Read more

Novo Nordisk, Vivtex collaborate on oral biologics for obesity, up to $2.1B in milestones
Research collaboration, metabolic diseases, oral biologics, milestone payments - Read more

Junshi Biosciences, Antengene collaborate to evaluate JS207 and ATG-037 combination therapy for solid tumors
Research collaboration, oncology, bispecific antibody, small molecule, combination therapy - Read more

Charles River Laboratories sells manufacturing and discovery businesses to GI Partners, IQVIA for strategic pivot
Asset divestiture, manufacturing, drug discovery, AI/ML, small molecule - Read more

The pathway to FDA can be difficult to navigate when precedent is limited, and frameworks are thin.

Facet specializes in helping emerging biotech teams understand what your program must demonstrate, how regulators are likely to evaluate the evidence, and what constitutes a viable, and ultimately, approvable, path forward.

It’s a regulatory strategy that starts where it should: with your science and your goals. Not the other way around.

Book a free 30-minute intro session with Facet → click here

Gilead's bictegravir/lenacapivir combo shows Ph2/3 non-inferiority results for human immunodeficiency virus treatment
Small molecule, infectious disease, HIV, combination therapy, integrase inhibitor, capsid inhibitor - Read more

Merck & Co's doravirine/islatravir meets Ph3 endpoints for HIV-1 treatment in treatment-naïve adults with regulatory submission planned
Small molecule, infectious disease, HIV-1, reverse transcriptase inhibitor, two-drug regimen - Read more

BridgeBio's Attruby reaches $146M Q4 sales, CEO dismisses EU generic competition concerns from Pfizer's patent withdrawal
Small molecule, cardiovascular, competitive, revenue impact - Read more

BreezeBio raises $60M Series B, genetic medicines using specialized nanoparticles
Gene therapy, autoimmune, oncology, nanoparticle delivery, preclinical - Read more

Basilea Pharmaceutica receives $6M BARDA funding for novel antibiotic development
Infectious disease, antibiotics, clinical-stage, small molecule - Read more

Zura Bio announces proposed public offering of Class A ordinary shares and warrants
Autoimmune, clinical-stage, inflammatory diseases - Read more

Bloom Science raises $11M Series A, microbiome-based weight loss therapy testing
Microbiome, neurological, weight loss, preclinical - Read more [Paywall]

Bicara Therapeutics raises $150M public offering for ficerafusp alfa development/commercialization
Clinical-stage, oncology, bifunctional therapies, solid tumors - Read more

Novartis selects Denton, Texas for fifth US radiopharmaceutical facility, generating $280M investment and 175 jobs
Radiopharmaceutical, oncology, operational, major transaction - Read more

GSK to buy 35Pharma for $950M, gaining pulmonary hypertension hopeful HS235
Small molecule, cardiovascular, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Accent terminates Ph1/2 study of ATX-559 DHX9 inhibitor for cancer due to adverse events
Small molecule, cancer, DHX9 inhibitor, Phase 1/2 trial termination, safety issues - Read more

Trump calls on Congress to codify Most Favored Nation drug pricing initiative into law during SOTU address
Drug pricing, regulatory, strategic, financial - Read more

15 Democrat-led states sue HHS over Trump administration's dramatic overhaul of childhood vaccination schedule
Vaccine, infectious disease, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here